Amgen's strong Q1 results, with revenues up 5% and adjusted EPS up 22%, exceeded expectations and demonstrate robust growth. The company reaffirmed revenue guidance, raised EPS outlook, and reported positive pipeline developments, including TVEC meeting its primary endpoint. These factors suggest positive momentum that is likely to drive the stock price upward in the short term.

[2]